Skip to main navigation Skip to search Skip to main content

Measuring respiratory symptoms in clinical trials of COPD: Reliability and validity of a daily diary

  • N. K. Leidy
  • , C. C. Sexton
  • , P. W. Jones
  • , S. M. Notte
  • , B. U. Monz
  • , L. Nelsen
  • , M. Goldman
  • , L. T. Murray
  • , S. Sethi
  • Pharmaceutical Product Development
  • St. George's Hospital Medical School
  • Boehringer Ingelheim GmbH
  • Merck
  • AstraZeneca

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Abstract

Background: Although respiratory symptoms are characteristic features of COPD, there is no standardised method for quantifying their severity in stable disease. Objective: To evaluate the EXACT-Respiratory Symptom (E-RS) measure, a daily diary comprising 11 of the 14 items in the Exacerbations of Chronic Pulmonary Disease Tool (EXACT). Methods: Qualitative: patient focus group and interviews to address content validity. Quantitative: secondary data analyses to test reliability and validity. Results: Qualitative: n=84; mean (SD) age 65(10) years, FEV1 1.2(0.4) L; 44% male. Subject descriptions of their respiratory symptoms were consistent with E-RS content and structure. Quantitative: n=188; mean (SD) age 66 (10) years, FEV1 1.2(0.5) L; 50% male. Factor analysis (FA) showed 3 subscales: RS-Breathlessness, RS-Cough & Sputum, and RS-Chest Symptoms; secondorder FA supported a general factor and total score. Reliability (total and subscales):0.88, 0.86, 0.73, 0.81; 2-day test-retest ICC: 0.90, 0.86, 0.87, 0.82, respectively. Validity: Total scores correlated significantly (p < 0.0001) with SGRQ Total (r=0.75), Symptoms (r=0.66), Activity (r=0.57), Impact (r=0.70) scores; subscale correlations were also significant (r=0.26, p < 0.05 (RS-Chest Symptoms with Activity) to r=0.69, p < 0.0001 (RS-Cough & Sputum with Symptoms). RS-Breathlessness correlated with rescue medication use (r=0.32, p < 0.0001), clinician-reported mMRC (r=0.33, p < 0.0001), and FEV1% predicted (r=-0.17, p < 0.05). E-RS scores differentiated groups based on chronic bronchitis diagnosis (p < 0.01-0.001), smoking status (p < 0.05-0.001), and rescue medication use (p < 0.05-0.0001). Conclusions: Results suggest the RS-Total is a reliable and valid instrument for evaluating respiratory symptom severity in stable COPD. Further study of sensitivity to change is warranted.

Original languageEnglish
Pages (from-to)443-449
Number of pages7
JournalThorax
Volume69
Issue number5
DOIs
StatePublished - May 2014

Fingerprint

Dive into the research topics of 'Measuring respiratory symptoms in clinical trials of COPD: Reliability and validity of a daily diary'. Together they form a unique fingerprint.

Cite this